Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage: ...

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), ...

There have been reports of bleeding or increased prothrombin time or both in patients taking pentoxifylline concomitantly with anticoagulants or antiplatelet agents. Although a causal relationship has ...

Peripheral arterial disease, also known as peripheral vascular disease, causes a build-up of fatty deposits in the arteries, making it harder for blood to get through and usually triggering symptoms ...

Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease. We ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...